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Alpha-synuclein is a predominant player in the pathogenesis of Parkinson’s Disease.
However, despite extensive study for two decades, its physiological and pathological
mechanisms remain poorly understood. Alpha-synuclein forms a perplexing web of
interactions with lipids, trafficking machinery, and other regulatory factors. One emerging
consensus is that synaptic vesicles are likely the functional site for alpha-synuclein,
where it appears to facilitate vesicle docking and fusion. On the other hand, the
dysfunctions of alpha-synuclein are more dispersed and numerous; when mutated
or over-expressed, alpha-synuclein affects several membrane trafficking and stress
pathways, including exocytosis, ER-to-Golgi transport, ER stress, Golgi homeostasis,
endocytosis, autophagy, oxidative stress, and others. Here we examine recent
developments in alpha-synuclein’s toxicity in the early secretory pathway placed in the
context of emerging themes from other affected pathways to help illuminate its underlying
pathogenic mechanisms in neurodegeneration.
Keywords: alpha-synuclein, vesicle trafficking, golgi, ER stress response, neurodegenerative diseases, Parkinson
disease, LRRK2, ER to golgi transport
INTRODUCTION
Alpha-synuclein (a-syn), a 14 kD cytosolic neuronal protein, has been a major focus of Parkinson’s
Disease (PD) pathological studies. As shown in Figure 1, a-syn consists of an N-terminal domain
that adopts an alpha-helical conformation upon binding to membranes, and a charged C-terminus
with multiple phosphorylation sites (Bendor et al., 2013; Snead and Eliezer, 2014). The N-terminal
domain of alpha-syn contains seven membrane-interacting repeats, and can either bind the
membrane as a long helix, or in a “broken helix” conformation with two helices connected by
a linker (Bartels et al., 2010). Alpha-syn monomers can either assemble into tetramers (Bartels
et al., 2011) or beta-sheet fibrils that aggregate to form Lewy bodies, a primary indicator
of Parkinson’s disease (PD) accompanied by neurodegeneration in the Substantia nigra, locus
coeruleus, and dorsal vagal nucleus (Kingsbury et al., 2010). Using a prion-like mechanism, normal
a-syn is converted to the aggregated form by a-syn molecules that have already been converted
(Deleersnijder et al., 2013), a process mediated by the non-amyloid-β component (NAC) region of
a-syn, comprising residues 61–95. Alpha-syn gene duplication, triplication, and several dominant
mutations, including A30P, E46K, H50Q, and A53T cause familial PD (Polymeropoulos et al., 1997;
Zarranz et al., 2004; Khalaf et al., 2014).
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FIGURE 1 | Alpha-synuclein structural schematic. Boxed regions represent alpha-helices. Seven repeats (residues 10–15, 21–26, 32–37, 43–48, 58–63, 69–74,
and 80–85) in the helical region are depicted with lighter shading. Numbering on figure refers to amino acids. PD-associated missense mutations are indicated.
Serine129 is a functionally implicated phosphorylation site. The C-terminal region contains a high density of charged residues (not shown).
The alpha-, beta-, and gamma-synuclein genes are somewhat
functionally redundant (Greten-Harrison et al., 2010; Ninkina
et al., 2012; Vargas et al., 2014), which probably accounts
for the lack of a significant phenotype from a-syn single
knockout (Abeliovich et al., 2000; Cabin et al., 2002). Synuclein
triple knockout, however, alters synapse structure and leads to
age-dependent neuronal dysfunction in mice (Greten-Harrison
et al., 2010). Alpha-syn participates in the maintenance of the
presynaptic vesicle pool as well as the release of neurotransmitter
(Murphy et al., 2000; Cabin et al., 2002; Ben Gedalya et al., 2009;
Nemani et al., 2010; Cheng et al., 2011).
The neuronal toxicity of alpha-synuclein over-expression or
mutation appears to involve a wide range of pathways and cellular
functions including ER-to-Golgi transport, Golgi homeostasis,
presynaptic trafficking, endocytosis, autophagy, the ubiquitin-
proteasome system, ER and oxidative stress (Snead and Eliezer,
2014). This review focuses primarily on the dysfunction of
alpha-synuclein and pathogenically related proteins in the early
secretory pathway.
PHYSIOLOGICAL FUNCTIONS
Although present in various compartments of the cell, alpha-
synuclein accumulates at the synapse (Maroteaux et al., 1988;
Kahle et al., 2000), and is recruited to synaptic vesicles through
interactions with specific lipids and trafficking machinery (Fortin
et al., 2004; Burré et al., 2010; Diao et al., 2013). In addition,
a-syn is capable of sensing membrane curvature and lipid
composition, with a preference for synaptic vesicle’s small shape,
high curvature, and charged lipid head groups (Pranke et al.,
2011; Bendor et al., 2013). The Rab family of small GTPases
appear to facilitate the recruitment process (Lee et al., 2011; Chen
et al., 2013) as does C-terminal phosphorylation (Oueslati et al.,
2010; Paleologou et al., 2010).
One emerging consensus is that a-syn, perhaps in cooperation
with cysteine string protein (CSP) (Chandra et al., 2005), acts as
a SNARE chaperone to potentiate SNARE assembly for fusion
(Burré et al., 2010). Interactions between a-syn and synaptic
SNAREs are established, and a-syn can promote SNARE-
mediated vesicle fusion in a manner that requires both lipid
and SNARE interactions. The precise step modulated by a-syn
seems to lie slightly upstream of final SNARE assembly during
clustering, docking, and/or SNARE priming for assembly (Diao
et al., 2013; Burré et al., 2014).
DYSFUNCTIONS I: THE SYNAPSE
Alpha-syn’s potential dysfunctions at its native site, the synapse,
have been intensely researched but will be briefly treated here.
Confusingly and despite the positive functions in docking and
fusion described above, a-syn has been shown to inhibit these
steps as well. Large alpha-syn oligomers potently inhibit vesicle
fusion (Choi et al., 2013, 2015) and soluble, non-aggregated
a-syn also inhibits at higher concentrations (Lai et al., 2014).
In some conditions, a-syn’s interactions with lipids alone may
inhibit SNARE-mediated fusion (DeWitt and Rhoades, 2013; Lai
et al., 2014). Alpha-syn synaptic function vs. dysfunction is likely
very sensitive to concentration and the aggregation state of a-syn
species, keeping inmind that conversion to pathogenic forms will
also deplete cells of the functional form. However, it remains to be
established whether a-syn synaptic dysfunction is a major driver
of neurodegeneration in PD.
DYSFUNCTIONS II: THE ER-GOLGI AXIS
The mechanism of a-syn toxicity leading to neurodegeneration is
very complex, multi-pronged, and highly integrated with cellular
stress pathways. Most likely, a-syn oligomers directly intoxicate
several cellular membrane-dependent pathways, each of which
causes damage and activation of unsuccessful stress responses
leading to apoptosis.
Evidence has mounted that one of the initiating insults results
from a-syn’s disruption of ER-to-Golgi transport, the first and
rate-limiting step in the biosynthetic secretory pathway. This
effect was first identified in a yeast screen for genetic suppressors
of a-syn toxicity (Cooper et al., 2006). Surprisingly, the
most efficient group of suppressors were membrane trafficking
proteins, including Ypt1p/rab1, which coordinates ER/Golgi
vesicle tethering; and Ykt6p, a SNARE that mediates ER/Golgi-
related fusions. That the most successful suppressors were
ER/Golgi trafficking machinery suggested that this pathway is
deeply involved in a-syn toxicity. Follow-up studies by multiple
groups have demonstrated potent inhibition of ER-to-Golgi
transport by physiologically relevant over-expression levels of
a-syn in normal rat kidney cells, HeLa cells, neuroendocrine
PC12 cells, and dopaminergic SH-SY5Y cells (Thayanidhi et al.,
2010; Winslow et al., 2010; Oaks et al., 2013). The evidence
supports a potent inhibition of the secretory pathway by
mild over-expression of wildtype a-syn and at even lower
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concentrations by PD-associated mutants. The locus of a-syn
inhibition appears to be post- ER budding, perhaps through
interference with rab- and SNARE-dependent COPII vesicle
tethering and/or fusion (Gitler et al., 2008; Thayanidhi et al.,
2010). Interestingly, superoxide dismutase-1 (SOD1) mutants
that cause neurodegeneration in amyotrophic lateral sclerosis
(ALS) have also been shown to inhibit ER-to-Golgi transport in
neurons resulting in ER stress that can be ameliorated by over-
expression of ER/Golgi vesicle machinery (Atkin et al., 2014). Is
there a common feature of aggregated cytosolic proteins that is
fundamentally linked to ER export?
Normal neurons may thus be treading a delicate balance in
which they must express a-syn at a sufficient level to promote
synaptic trafficking yet below a threshold where it inhibits
biosynthetic trafficking and causes stress in the cell body. How
can a-syn be on the one hand a chaperone for facilitating
SNARE-dependent synaptic vesicle docking/fusion, and on the
other hand a disruptor of mechanistically similar membrane
docking/fusion events in the early secretory pathway? One key
could be the membrane binding properties of a-syn, which
cause it to preferentially interact with post-Golgi, highly curved,
charged membranes (Pranke et al., 2011) and lead the N-
terminal region to adopt helical structure and self-aggregate
(Burré et al., 2014). If these membrane interactions affect a-syn
interactions with SNAREs and rabs, then perhaps only post-
Golgi lipid compositions support positive effects. Conversely, a-
syn molecules that are not properly primed by lipid interactions
would fail to exert positive effects, or even negatively affect
SNARE assembly on pre-Golgi membranes. Both SNAREs and
a-syn undergo binding-induced helix formation, which could
make their coordinated assembly extremely context dependent.
It would be very useful to know whether a-syn can have different
effects at distinct membrane trafficking steps under the same
expression conditions in the same cell.
Recently, the link between ER/Golgi trafficking and PD
became even stronger. Mutations in Leucine-rich repeat kinase
2 (LRRK2) are the most frequent genetic lesions associated with
PD (Kumari and Tan, 2009). Strong genetic and possible physical
interactions between a-syn and LRRK2 suggest that they may
intoxicate a common pathway (Lin et al., 2009; Qing et al.,
2009; Guerreiro et al., 2013). While the precise functions of
LRRK2 are still emerging, they appear to be converging on ER
export and secretory trafficking. Interactions between LRRK2
and the ER exit site (ERES) scaffold sec16 led to the discovery
that LRRK2 is required for ERES assembly and efficient ER
cargo exit (Cho et al., 2014). Sec16 is believed to work in
concert with Sar1 GTPase to facilitate the assembly of COPII
coat components (Watson et al., 2006). One of the common PD-
associated LRRK2 mutants, R1441C, disrupts targeting of sec16
to ERES. In parallel, another mechanism by which LRRK2 may
impact secretion has emerged. Screens for LRRK2 interactions
identified BCL2-associated athanogene 5 (BAG5), Rab7L1, and
cyclin-G–associated kinase (GAK) as binding partners. These
proteins appeared to form a single complex targeted to the TGN
that positively regulates TGN turnover (Beilina et al., 2014).
Over-expression of any of these proteins alone, or expression
of PD-associated mutations of LRRK2, led to ablation of TGN
markers, and presumably the organelle itself, via an autophagy
mechanism (Beilina et al., 2014). Severe down-regulation of the
TGN would disrupt secretory trafficking and ultimately lead to
intracellular accumulation of secretory cargo at multiple steps.
Elucidating the multiple cellular functions of LRRK2 is essential
for understanding the secretory pathology of PD. Another
development was that rab39b lesions are associated with early-
onset Parkinsonism (Wilson et al., 2014). Although still very
early, it appears that rab39b and protein interacting with C-
kinase 1 (PICK1) regulate ER-to-Golgi transport of synaptic
machinery (Mignogna et al., 2015). To summarize, genetic lesions
in a-syn, LRRK2 and other genes–including the most potent
and frequent lesions causing PD–may initiate neuronal stress
by disrupting early steps in secretion. It is urgent to elucidate
the complex relationship between ER/Golgi trafficking, neuronal
stress, and PD.
Alpha-syn probably disrupts intra-Golgi and post-Golgi
secretory trafficking in addition to ER-to-Golgi trafficking.
Alpha-syn interacts with Rab8 (Golgi), Rab3a (post-Golgi), and
Rab5 (early endosomal) in a-syn A30P transgenic mice (Dalfó
et al., 2004); in addition, Rab8 (Golgi), Rab3a (post-Golgi),
and rab11 (recycling endosomal) overexpression rescue alpha-
syn’s toxicity (Cooper et al., 2006; Gitler et al., 2008; Yin
et al., 2014; Breda et al., 2015). That a-syn toxicity involves
simultaneous block of multiple steps in the biosynthetic secretory
pathway is also supported by the potent suppression of a-syn
transport blocks by ykt6 (Cooper et al., 2006; Thayanidhi et al.,
2010), an R-SNARE that can participate in multiple fusogenic
SNARE complexes. One secretory cargo of particular importance
to dopaminergic neurons is the dopamine transporter (DAT);
indeed DAT accumulates in microsomal fractions upon a-syn
over-expression and dopamine uptake is consequently inhibited
(Oaks et al., 2013). However, as outlined below, ER accumulation,
as opposed to lack of proper delivery of secretory and membrane
proteins may drive neurodegeneration even more substantially.
DYSFUNCTIONS III: ER STRESS
Alpha-syn over-expression causes ER stress (ERS) and activation
of the unfolded protein response (UPR) in cellular models (Smith
et al., 2005), which causes apoptosis if unresolved. Accumulating
evidence from many systems and approaches indicates that UPR
plays a rate-limiting role in the progression of neurodegeneration
and a-syn pathology (Mercado et al., 2013). UPR is activated
in PD neurons and UPR modulation protects or potentiates
PD progression. Low levels of UPR protects neurons from a-
syn toxicity, presumably by inducing chaperones and secretory
machinery to counteract ERS (Fouillet et al., 2012; Valdés
et al., 2014). Similarly, prevention of the adaptive response or
inducing acute ERS accelerates a-syn-associated neuronal death
(Colla et al., 2012a; Salganik et al., 2015). Phosphorylation of
Ser129 on alpha-syn appears to be important for triggering UPR
(Colla et al., 2012a). Interestingly, a-syn intoxication does not
activate all three classical branches of the UPR equally, which
could help explain why this particular ERS cannot be adapted
to. Work in PD models found that induction of chaperones
and CHOP occurs without phosphorylation of eIF2α by PERK
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(Colla et al., 2012a), perhaps indicating that adaptive and pro-
apoptotic responses are out of balance. Other studies indicate
that activation of IRE1/XBP1 is key to neuronal survival in
PD, and that this particular UPR branch may be selectively
important in neurons of the substantia nigra (Valdés et al.,
2014). Still other work finds that a-syn toxicity involves the
imbalanced outcomes of increased chaperones accompanied by
decreased activation of the ATF6 pathway (Credle et al., 2015).
A compelling correlate of this hypothesis is that activation
of the ATF6 pathway requires ER/Golgi transport, and ATF6
export from the ER is potently inhibited by a-syn (Credle et al.,
2015).
Precisely how does a-syn cause ERS in the first place? Themost
obvious mechanism would be inhibition of ER/Golgi transport
and/or later steps in the biosynthetic secretory pathway, leading
to ER overload. The finding that over-expression of secretory rabs
and other machinery alleviates a-syn toxicity is consistent with
ERS originating from a trafficking defect (Gitler et al., 2008; Yin
et al., 2014). However, ER/Golgi transport could also be viewed
as a relief valve for ERS caused by perturbation of other ER
functions. In addition, some of the secretory machinery whose
expression rescues stress, rab1a for example, may also more
directly regulate UPR events or autophagy induction (Winslow
et al., 2010; Chua and Tang, 2013).
Evidence exists for several modes by which a-syn could initiate
ERS through mechanisms distinct from ER/Golgi trafficking. For
example, it has been suggested that a-syn may find its way inside
the lumen of the ER, where it could aggregate with chaperones
to cause ERS (Colla et al., 2012b). A mechanism for a-syn
to cross the ER membrane has not been demonstrated. One
speculation could be uptake of extracellular a-syn aggregates by
endocytosis followed by retrograde vesicular transport to the ER
lumen, as in the case of certain bacterial toxins (Spooner and
Lord, 2012). A completely distinct mechanism by which a-syn
may trigger ERS is by inhibition of ER associated degradation
(ERAD), which would cause buildup of excess unfolded proteins.
Homocysteine-induced ER protein (Herp) is overexpressed in
PD and is a component of Lewy bodies (Slodzinski et al.,
2009) whose knockdown sensitizes PC12 cells to ERS-induced
apoptosis and a-syn toxicity (Belal et al., 2012). Herp plays an
essential role in ERAD (Schulze et al., 2005), particularly ERAD-
dependent turnover of ER calcium channels (Belal et al., 2012).
Herp inhibition or aggregation in PD could lead to general
ERAD inhibition or ER calcium depletion, either of which
could cause ERS. ERAD relies upon the ubiquitin-proteasome
system (UPS) for the disposal of ER-dislocated substrates, and
there are many links between the UPS and PD, only discussed
here as it relates to ERS. Several E3 ubiquitin ligases, for
example parkin, HRD1 and Rsp5/Nedd4, can protect cells from
a-syn intoxication and ERS (Tsai et al., 2003; Omura et al.,
2013; Tardiff et al., 2013). The mechanism by which ubiquitin
ligases protect neurons from ERS is unclear. One possibility
is that the UPS contributes to the removal of specific stress-
causingmembrane proteins such as parkin-associated endothelin
receptor-like receptor (Pael-R) that have been implicated in PD
pathology (Kitao et al., 2007; Omura et al., 2013). Parkin also
triggers mitophagy when recruited to defective mitochondria by
the voltage sensor PINK (Kroemer et al., 2010). But there could
also be more fundamental link(s) whereby the UPS promotes ER
homeostasis, for example through a direct regulatory role in the
initiation of UPR, ERAD, or ER-phagy. This could help explain
why multiple neurodegenerative diseases involving aggregated
cytosolic proteins result in UPR–a process conventionally viewed
as initiated in the ER lumen.
DYSFUNCTIONS IV: GOLGI HOMEOSTASIS
Golgi fragmentation is commonly observed in PD as well as
other neurodegenerative diseases (Gonatas et al., 2006; Fan
et al., 2008; Bexiga and Simpson, 2013). Overexpression of a-
syn in cultured mammalian cell lines and neurons can lead to
Golgi fragmentation; formation of a-syn prefibrillar aggregates
correlates tightly with Golgi and microtubule disruption (Gosavi
et al., 2002; Lee et al., 2006). Alpha-syn accumulation in yeast
results in mislocalization of Golgi markers and aggregation
of secretory vesicles (Soper et al., 2008, 2011). However, the
functional and pathological significance of Golgi disruption
remains unclear. In some cases, Golgi disruption seems to
precede microtubule disruption and inhibition of ER/Golgi
transport (Rendón et al., 2013), implying that Golgi disruption
is not a result of the trafficking block, and could represent an
independent branch of the pathology. In other cases the Golgi
disruption seems to accompany and be due to the ER/Golgi
transport inhibition (Coune et al., 2011) or be absent during
transport inhibition (Thayanidhi et al., 2010).
The lack of a consistent correlation between ER/Golgi
transport inhibition and Golgi disruption makes the role of Golgi
homeostasis in PD hard to evaluate. However, an intriguing
idea is that Golgi dispersal may be a means to propagate an a-
syn-caused Golgi-based stress signal. Increased neuronal firing
activity causes reversible Golgi fragmentation, suggesting it may
be part of a homeostatic stress signaling mechanism (Thayer
et al., 2013). Furthermore, inhibition of Golgi dispersal through
over-expression of Golgi tethering proteins can reduce the
toxicity of chemically-induced ER or oxidative stress (Nakagomi
et al., 2008). How Golgi fragmentation is initiated in response
to a-syn remains unclear, but signaling mechanisms mediating
other stress-related Golgi fragmentation have been outlined. For
example, the small GTPase ADP-ribosylation factor 4 (ARF4)
initiates Golgi dispersal in response to pathogens and chemical
insults (Reiling et al., 2013), and Cdk5 kinase phosphorylation of
Golgi matrix protein 130 (GM130) may mediate Golgi dispersal
in neurons challenged with beta-amyloid (Sun et al., 2008). It
would be exciting to test whether blockade of Golgi-dispersing
signals can relieve a-syn toxicity.
THE ENDOLYSOSOMAL SYSTEM AND
ALPHA-SYNUCLEIN CLEARANCE
The importance of the endolysosomal system in a-syn toxicity
cannot be overstated but will only be briefly introduced. The
clearance of a-syn largely depends upon the endosome-lysosome
pathway (Flower et al., 2007; Lee et al., 2008; Liu et al., 2009;
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FIGURE 2 | Summary of the roles of alpha-synuclein and other PD-associated proteins in the secretory pathway and the resulting stress responses.
Alvarez-Erviti et al., 2011). This process appears to be Rab11a-
dependent (Liu et al., 2009), which likely explains Rab11a’s
involvement in synucleinopathy (Breda et al., 2015). Alpha-syn
over-expression appears to interfere with endosomal trafficking
(Soper et al., 2008, 2011; Volpicelli-Daley et al., 2014), and
this likely exacerbates a-syn toxicity by potentiating a-syn
accumulation. In addition, impaired lysosomal activity could
contribute to PD (van Dijk et al., 2013).
Alpha-syn accumulation triggers macroautophagy, the
process by which cytosolic proteins and organelles are imported
into lysosomes. ERS triggered by a-syn accumulation probably
contributes to autophagy activation since the PERK and ATF6
UPR signaling arms induce autophagy genes (He and Klionsky,
2009; Kroemer et al., 2010). However, aggregated or over-
expressed alpha-syn inhibits autophagy and results in less
efficient clearance, more accumulation and greater cell-to-cell
spread of a-syn pathology (Winslow et al., 2010; Lee et al., 2013;
Tanik et al., 2013).
OXIDATIVE STRESS
Oxidative stress is another outcome of alpha-syn accumulation,
and is closely associated with disruption of ER proteostasis
(Exner et al., 2012). Similar to ERS, mitochondrial dysfunction
is present in many neurodegenerative diseases (Lionaki et al.,
2015), and will be important in disease intervention. Still, a
key question remaining is whether the pathological oxidative
stress is a downstream manifestation of other stresses, for
example perturbed ER calcium or reduced autophagic clearance
of defective mitochondria (Chigurupati et al., 2009; Su et al.,
2010), or does it belie a more fundamental relationship with
alpha-synuclein?
CONCLUSION
We have briefly summarized the multifaceted effects of
alpha-syn on cellular membrane trafficking, with special
emphasis on the ER-Golgi axis (see Figure 2). Many more
studies will be required to unravel all of the mechanisms
of alpha-syn toxicity, and the early secretory pathway will
likely remain a major focus. One of the major issues to
resolve is how a-syn manages to play positive as well negative
roles in membrane trafficking due to its concentration,
aggregation state, and SNARE- and lipid-binding properties.
Another major issue is how a-syn triggers its unique kind
of ERS and how this stress is modulated by ER/Golgi
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transport, ERAD, and the ubiquitin-proteasome system.
In addition, it should be resolved whether there is a
common pattern of dysfunction in the early secretory
pathway lying at the heart of multiple neurodegenerative
diseases.
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